参考文献/References:
[1] Savarese G,Becher PM,Lund LH,et al. Global burden of heart failure:a comprehensive and updated review of epidemiology[J]. Cardiovasc Res,2023,118(17):3272-3287.
[2] 李晓洁,许泽鹏,黄玉婷,等. Toll样受体4信号通路在糖尿病视网膜病变中的研究进展[J].中国中医眼科杂志,2023,33(1):73-79.
[3] Deguchi A,Maru Y. Inflammation-associated premetastatic niche formation[J]. Inflamm Regen,2022,42(1):22.
[4] Zhang S,Chen F,Zhai F,et al. Role of HMGB1/TLR4 and IL-1β/IL-1R1 signaling pathways in epilepsy[J]. Front Neurol,2022,13:904225.
[5] Sumneang N,Apaijai N,Chattipakorn SC,et al. Myeloid differentiation factor 2 in the heart:Bench to bedside evidence for potential clinical benefits?[J]. Pharmacol Res,2021,163:105239.
[6] Ciesielska A,Matyjek M,Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling[J]. Cell Mol Life Sci,2021,78(4):1233-1261.
[7] Xiao Z,Kong B,Yang H,et al. Key Player in cardiac hypertrophy,emphasizing the role of Toll-like receptor 4[J]. Front Cardiovasc Med,2020,7:579036.
[8] Zhang Y,Liang X,Bao X,et al. Toll-like receptor 4 (TLR4) inhibitors:current research and prospective[J]. Eur J Med Chem,2022,235:114291.
[9] 梁魏昉. 心力衰竭患者TLR4/NF-κB信号通路、vWF、D-二聚体水平变化及其与心力衰竭程度、LVEF的相关性分析[J]. 中西医结合心脑血管病杂志,2022,20(5):887-892.
[10] 文仙仙,张娜,王兴兴,等. Toll样受体4信号通路对慢性心力衰竭患者心血管事件的预测[J].心肺血管病杂志,2023,42(6):547-552.
[11] 章敬玉,李志华,陈健. 上呼吸道感染伴急性心力衰竭患者外周血HMGB1和TLR4水平与心脏功能的关系[J]. 热带医学杂志,2023,23(7):964-968.
[12] 王国玉,王淼,李彤,等. 慢性心力衰竭合并社区获得性肺炎患者血清TLR4表达及与PCT、NT-proBNP、氧化应激指标的相关性分析[J]. 中国现代医学杂志,2023,33(7):60-65.
[13] Tamargo J,Caballero R,Delpon E. New drugs in preclinical and early stage clinical development in the treatment of heart failure[J]. Expert Opin Investig Drugs,2019,28(1):51-71.
[14] Dutka M,Bobinski R,Ulman-Wlodarz I,et al. Sodium glucose cotransporter 2 inhibitors:mechanisms of action in heart failure[J]. Heart Fail Rev,2021,26(3):603-622.
[15] Yang J,Wise L,Fukuchi KI. TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer’s disease[J]. Front Immunol,2020,11:724.
[16] Byrne NJ,Matsumura N,Maayah ZH,et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure[J]. Circ Heart Fail,2020,13(1):e6277.
[17] Eiringhaus J,Wünsche CM,Tirilomis P,et al. Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure[J]. ESC Heart Fail ,2020,7(5):2992-3002.
[18] Koyani CN,Plastira I,Sourij H,et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation[J]. Pharmacol Res,2020,158:104870.
[19] Mustroph J,Wagemann O,Lucht CM,et al. Empagliflozin reduces Ca/calmodulin-dependent kinase Ⅱ activity in isolated ventricular cardiomyocytes[J]. ESC Heart Fail,2018,5(4):642-648.
[20] Kang H,Zhang J,Zhang X,et al. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease:a meta-analysis[J]. Eur J Pharmacol,2020,884:173444.
[21] Shen J,Fan Z,Sun G,et al. Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3?induced pyroptosis via the TAK1/JNK signaling pathway[J]. Mol Med Rep,2021,24(3):676.
[22] Bunsawat K,Ratchford SM,Alpenglow JK,et al. Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction[J]. J Appl Physiol (1985),2021,130(1):256-268.
[23] Luo X,Hu Y,He S,et al. Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation[J]. Arch Biochem Biophys,2019,671:203-209.
[24] Fu Z,Mui D,Zhu H,et al. Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models[J]. Aging (Albany NY),2020,12(9):8640-8651.
[25] Ma G,Liu Y,Wang Y,et al. Liraglutide reduces hyperglycemia-induced cardiomyocyte death through activating glucagon-like peptide 1 receptor and targeting AMPK pathway[J]. J Recept Signal Transduct Res,2020,40(2):133-140.
[26] Meng J,Zhang W,Wang C,et al. The dipeptidyl peptidase (DPP)-4 inhibitor trelagliptin inhibits IL-1β-induced endothelial inflammation and monocytes attachment[J]. Int Immunopharmacol,2020,89(Pt B):106996.
[27] Baylan U,Korn A,Emmens RW,et al. Liraglutide treatment attenuates inflammation markers in the cardiac,cerebral and renal microvasculature in streptozotocin-induced diabetic rats[J]. Eur J Clin Invest,2022,52(9):e13807.
相似文献/References:
[1]吴亚希,杨丽霞.Toll样受体4与心血管疾病的研究进展[J].心血管病学进展,2016,(1):58.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.015]
WU Yaxi,YANG Lixia.Research Progress of Relationship Between Toll-like Receptor 4 and
Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(5):58.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.015]
[2]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[3]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(5):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[4]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(5):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[5]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(5):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[6]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(5):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[7]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[8]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[9]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[10]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]